Extracellular vesicle最新文献

{"title":"Unveiling the intricacies of bone homeostasis: Epigenetic regulation, extracellular vesicles, and angiogenesis integration","authors":"Célio Junior da Costa Fernandes","doi":"10.1016/j.vesic.2024.100042","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100042","url":null,"abstract":"<div><p>Bone homeostasis is a complex process involving the coordinated actions of various bone cells and their interactions with the surrounding microenvironment. Epigenetic regulation, specifically through DNA methylation, histone acetylation, microRNAs, and long non-coding RNAs, has been identified as a crucial factor in maintaining bone health. Furthermore, the interplay between bone cells and angiogenesis, the process of forming new blood vessels, plays a critical role in maintaining bone health. Epigenetic factors have been found to regulate angiogenesis in bone tissue. Extracellular vesicles derived from different cell types, such as osteoblasts, endothelial cells, and mesenchymal stem cells, are also important in bone homeostasis. These vesicles transport bioactive molecules, including microRNAs, growth factors, and cytokines, which regulate angiogenesis and influence the function of bone cells. Understanding the epigenetic control of gene expression and the role of extracellular vesicles in bone homeostasis has significant implications for the development of therapeutic strategies for bone disorders. This knowledge is particularly valuable in the context of aging, metabolic disorders, and pathological disruptions of bone homeostasis.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277304172400009X/pdfft?md5=9e81a1d892cc1d259549aeb9203ca394&pid=1-s2.0-S277304172400009X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140901820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicle lyophilization for enhanced distribution to the point of care","authors":"Morgane E. Golan ,&nbsp;Steven L. Stice","doi":"10.1016/j.vesic.2024.100041","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100041","url":null,"abstract":"<div><p>Therapeutic extracellular vesicles (EVs) are in clinical trials and if successful, EVs wider use will be largely affected by costs to patients/insurers and accessibility. EV preservation-storage efficiencies directly factor into both of these considerations. EV cryopreservation drives up costs and relies on the pharmaceutical cold chain, which is expensive and among the most pressing barriers to widespread access of medicines. Lyophilization preserves biological materials at room temperature, thereby enhancing storage while circumventing the cold chain. Here we describe the factors influencing EV storage and lyophilization processes which may improve accessibility of EV therapies.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100041"},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000088/pdfft?md5=a734182959042032c44efc4b546c400b&pid=1-s2.0-S2773041724000088-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140880327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EV antibody database: An interactive database of curated antibodies for extracellular vesicle and nanoparticle research","authors":"Amber Morey ,&nbsp;Martin Ng ,&nbsp;Michail Spanos ,&nbsp;Piyan Zhang ,&nbsp;Tuoye Xu ,&nbsp;Willi Cheung ,&nbsp;Emeli Chatterjee ,&nbsp;Priyanka Gokulnath ,&nbsp;Natacha Carnel-Amar ,&nbsp;Ana Luisa Soares Chiaretti ,&nbsp;Collin Nelson ,&nbsp;Jubin George ,&nbsp;Michelle Luo ,&nbsp;Abhik Chakraborty ,&nbsp;Luiza Perucci ,&nbsp;Jennifer C. Jones ,&nbsp;Peter De Hoff ,&nbsp;Jeffrey L. Franklin ,&nbsp;Robert L. Raffai ,&nbsp;Saumya Das ,&nbsp;Roger P. Alexander","doi":"10.1016/j.vesic.2024.100040","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100040","url":null,"abstract":"<div><p>Antibodies are critical tools for research into extracellular vesicles (EVs) and other extracellular nanoparticles (ENPs), where they can be used for their identification, characterization, and isolation. However, the lack of a centralized antibody platform where researchers can share validation results thus minimizing wasted personnel time and reagents, has been a significant obstacle. Moreover, because the performance of antibodies varies among assay types and conditions, detailed information on assay variables and protocols is also of value. To facilitate sharing of results on antibodies that are relevant to EV/ENP research, the EV Antibody Database has been developed by the investigators of the Extracellular RNA Communication Consortium (ERCC). Hosted by the ExRNA Portal (https://exrna.org/resources/evabdb/), this interactive database aggregates and shares results from antibodies that have been tested by research groups in the EV/ENP field. Currently, the EV Antibody Database includes modules for antibodies tested for western Blot, EV Flow Cytometry, and EV Sandwich Assays, and holds 110 records contributed by 6 laboratories from the ERCC. Detailed information on antibody sources, assay conditions, and results is provided, including negative results. We encourage ongoing expert input and community feedback to enhance the database's utility, making it a valuable resource for comprehensive validation data on antibodies and protocols in EV biology.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000076/pdfft?md5=9bd26acaef87b31faeecd4c539c95bbd&pid=1-s2.0-S2773041724000076-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140645883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles for breast cancer diagnosis and therapy","authors":"Jianan Shi ,&nbsp;Huan Zhang ,&nbsp;Yaxin Cui ,&nbsp;Jianming Xing ,&nbsp;Wei Wang ,&nbsp;Jiayi Chen ,&nbsp;Simiao Wang ,&nbsp;Zhaogang Yang","doi":"10.1016/j.vesic.2024.100039","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100039","url":null,"abstract":"<div><p>Breast cancer is still suffering from its poor diagnosis and the lack of effective treatment. Despite of recent development of some novel chemicals, which are found to have inspiring therapeutic effects <em>in vitro,</em> their outcomes in clinic trails are disappointing, mainly due to the lack of suitable therapeutic vehicles. Thanks to their ability to encapsulate bio-molecules, extracellular vesicles (EVs), including exosomes, microvesicles, and apoptotic bodies, hold great promise in becoming a suitable candidate in the breast cancer diagnosis and therapy. Currently, EVs are increasingly evaluated as potential indicators in the diagnosis of breast cancer since they are actively involved in different stages of breast cancer development, including promoting cancer occurrence and metastasis, establishing tumor ecology, and promoting tumor growth. Moreover, they are also considered as promising new platforms in breast cancer therapy. Here, we discuss the potential therapeutic applications of EVs, including EVs as biomarkers for diagnosis and therapeutic drug delivery to tumor sites. The promising data and technologies indicate the potential applicability of EVs in clinical management of patients with breast cancer.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100039"},"PeriodicalIF":0.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000064/pdfft?md5=ca423fe653b25f78621e45cbe36ef496&pid=1-s2.0-S2773041724000064-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140643844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic insights uncover enhanced neurotherapeutic potential in conditioned mesenchymal stem cell-derived extracellular vesicles","authors":"Junxiu Xi ,&nbsp;Tian Wang ,&nbsp;Panpan Xian ,&nbsp;Xiaoyan Liu ,&nbsp;Minghao Du ,&nbsp;Hao Yang ,&nbsp;Perumal Palanisamy Chella ,&nbsp;Wei Lin ,&nbsp;Qianfa Long","doi":"10.1016/j.vesic.2024.100037","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100037","url":null,"abstract":"<div><p>Extracellular vesicles (EVs) show more potential as therapeutic agents for treating neurological disorders than their parent cells like MSCs. Notably, the therapeutic efficacy of MSCs can be boosted by inflammation factors and oxidative stressors. Here, we investigated the impact of activated microglial cell supernatant (Con1) and hydrogen peroxide (Con2) on MSCs and collected their derived EVs, followed by using high-resolution mass spectrometry to analyze MSC-EV proteomic and phosphoproteomic profiles, and verified the indicated functional protein and phosphorylated kinase as well. Our findings showed that both Con1 and Con2 EVs exhibited characteristic features of extracellular vesicles and possessed greater anti-inflammatory and antioxidant activity compared to unconditioned MSC-EVs. Omics analysis revealed alterations in protein expression and phosphorylation associated with inflammation and oxidation biological processes and signaling pathways, as well as signified the post-translational modification of proteins in Con1/2 EVs. Importantly, we identified that the anti-inflammatory role of MSC-EVs was linked to the serine/threonine kinase phosphorylation, and inhibition of insulin-like growth factor 1 receptor (IGF1R) reduced the antioxidant activity of MSC-EVs. This report documented the changed protein expression and phosphorylated patterns of Con1/2 EVs, and provided insights into the functionalization mode of MSC-EVs, suggesting the enhanced neurotherapeutic potential of conditioned EVs in the treatment of neurological diseases.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000040/pdfft?md5=6fe6eb9daf901a73237c70837af66884&pid=1-s2.0-S2773041724000040-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140620737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring emerging concepts of exosomes for the diagnosis, prognosis, and therapeutics of brain cancers","authors":"Subhrajyoti Banerjee,&nbsp;Vriti Sharma,&nbsp;Chitrangada Das Mukhopadhyay","doi":"10.1016/j.vesic.2024.100038","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100038","url":null,"abstract":"<div><p>Brain cancers, a global menace with high mortality rates, remain a profound challenge, particularly in treating the most lethal type of malignant tumors like glioblastoma multiforme (GBM). The crucial need for prompt identification and precise prognosis drives the exploration of exosomes as non-invasive tools. Exosomes are generated by various cells, especially malignant cells, facilitating intercellular communication in the tumor microenvironment, fostering glioma progression by conveying molecular modifiers, and offering molecular insights. These attributes hold promise for enhancing glioma diagnosis and prognosis. These nanosized messengers influence cancer dynamics, aiding tailored treatment strategies for improved patient outcomes. This article outlines the significance of exosomes in glioma progression, highlighting recent advancements in diagnostic and therapeutic strategies utilizing bioactive molecules as biomarkers like miRNAs, circ-RNAs, genes, and proteins in a variety of brain tumors, supported by advanced isolation and identification techniques. The relevance of circulating exosomes to various brain malignancies particularly glioblastoma, astrocytoma, craniopharyngiomas, meningioma, and more, has been discussed. It elucidates tumor immune cross-talk and underscores diagnostic-worthy exosomal biomarkers like miRNAs, circ-RNAs, genes, and proteins. Additionally, it delineates promising avenues for forthcoming investigations.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2024-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000052/pdfft?md5=800612686c103af535500b037ca6ecd0&pid=1-s2.0-S2773041724000052-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140621949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exosome therapy in female reproductive aging","authors":"Mengtong Zhang ,&nbsp;Sichen Zhang ,&nbsp;Shaowei Wang","doi":"10.1016/j.vesic.2024.100036","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100036","url":null,"abstract":"<div><p>As life expectancy continues to extend, the adverse effects of reproductive aging on female health have become progressively conspicuous. Despite the extant focus on symptom alleviation, a paucity of pharmaceutical interventions addresses the underlying causative factors. Exosome therapy, acknowledged for its relatively safe cell-free approach, emerges as a promising avenue. Notably, exosomes derived from stem cells exhibit comparable efficacy to their cellular counterparts. Nevertheless, extant methodologies for exosome production exhibit several limitations, particularly in achieving high-caliber, large-scale manufacturing. Consequently, this review is dedicated to elucidating the ongoing research endeavors and advancements of exosome therapy pertaining to the female reproductive aging.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000039/pdfft?md5=11eddf30d49e0634cf714c1960cb80f4&pid=1-s2.0-S2773041724000039-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140351948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding molecular characteristics of extracellular vesicles derived from different types of mesenchymal stem cells for therapeutic translation","authors":"Zuo Ding ,&nbsp;Zachary F. Greenberg ,&nbsp;Maria Fernanda Serafim ,&nbsp;Samantha Ali ,&nbsp;Julia C. Jamieson ,&nbsp;Dmitry O. Traktuev ,&nbsp;Keith March ,&nbsp;Mei He","doi":"10.1016/j.vesic.2024.100034","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100034","url":null,"abstract":"<div><p>Mesenchymal stem cells (MSCs) have been studied for decades as candidates for cellular therapy, and their secretome, including secreted extracellular vesicles (EVs), has been identified to contribute significantly to regenerative and reparative functions. Emerging evidence has suggested that MSC-EVs alone, could be used as therapeutics that emulate the biological function of MSCs. However, just as with MSCs, MSC-EVs have been shown to vary in composition, depending on the tissue source of the MSCs as well as the protocols employed in culturing the MSCs and obtaining the EVs. Therefore, the importance of careful choice of cell sources and culture environments is receiving increasing attention. Many factors contribute to the therapeutic potential of MSC-EVs, including the source tissue, isolation technique, and culturing conditions. This review illustrates the molecular landscape of EVs derived from different types of MSC cells along with culture strategies. A thorough analysis of publicly available omic datasets was performed to advance the precision understanding of MSC-EVs with unique tissue source-dependent molecular characteristics. The tissue-specific protein and miRNA-driven Reactome ontology analysis was used to reveal distinct patterns of top Reactome ontology pathways across adipose, bone marrow, and umbilical MSC-EVs. Moreover, a meta-analysis assisted by an AI technique was used to analyze the published literature, providing insights into the therapeutic translation of MSC-EVs based on their source tissues.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000015/pdfft?md5=fd73befeeaf3fda864de7baf5d943dab&pid=1-s2.0-S2773041724000015-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140016031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-organ, feto-maternal interface organ-on-chip, models pregnancy pathology and is a useful preclinical extracellular vesicle drug trial platform","authors":"Melody Safarzadeh ,&nbsp;Lauren S. Richardson ,&nbsp;Ananth Kumar Kammala ,&nbsp;Angela Mosebarger ,&nbsp;Mohamed Bettayeb ,&nbsp;Sungjin Kim ,&nbsp;Po Yi Lam ,&nbsp;Enkhtuya Radnaa ,&nbsp;Arum Han ,&nbsp;Ramkumar Menon","doi":"10.1016/j.vesic.2024.100035","DOIUrl":"https://doi.org/10.1016/j.vesic.2024.100035","url":null,"abstract":"<div><p>Pregnant women and their fetuses are often excluded from clinical trials due to missing drug-related pre-clinical trial information at the human feto-maternal interface (FMi). The two interfaces-placenta/decidua and fetal membranes/decidua are gatekeepers of drug transport; however, testing their functions is impractical during pregnancy. Limitations of current <em>in-vivo</em>/<em>in-vitro</em> models have hampered drug development and testing during pregnancy. Hence, major complications like preterm births and maternal and neonatal mortalities remain high. Advancements in organ-on-chip (OOC) platforms to test drug kinetics and efficacy and novel extracellular vesicle-based fetal drug delivery are expected to accelerate preclinical trials related to pregnancy complications. Here we report the development and testing of a humanized multi-organ fetal membrane/placenta (fetal)-decidua (maternal) interface OOC (FMi-PLA-OOC) that contains seven cell types interconnected through microchannels to maintain intercellular interactions as seen <em>in-utero</em>. Cytotoxicity, propagation, mechanism of action, and efficacy of engineered extracellular vesicles containing anti-inflammatory interleukin (IL)-10 (eIL-10) were evaluated to reduce FMi inflammation associated with preterm birth. A healthy and disease model (lipopolysaccharide-infectious inflammation) of the FMi-PLA-OOC was created and co-treated with eIL-10. eIL-10 propagated from the maternal to fetal side within 72-h, localized in all cell types, showed no cytotoxicity, activated IL-10 signaling pathways, and reduced lipopolysaccharide-induced inflammation (minimized NF-kB activation and proinflammatory cytokine production). These data recapitulated eIL-10s’ ability to reduce inflammation and delay infection-associated preterm birth in mouse models, suggesting FMi-PLA-OOC as an alternative approach to using animal models. Additionally, we report the utility of eIL-10 that can traverse through FMis to reduce inflammation-associated pregnancy complications.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100035"},"PeriodicalIF":0.0,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041724000027/pdfft?md5=63caf11b5cb6a26a47eac9627586afec&pid=1-s2.0-S2773041724000027-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139935906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A simple scalable extracellular vesicle isolation method using polyethylenimine polymers for use in cellular delivery","authors":"Marie Ange Djeungoue Petga ,&nbsp;Catherine Taylor ,&nbsp;Alexander Macpherson ,&nbsp;Surendar Reddy Dhadi ,&nbsp;Thomas Rollin ,&nbsp;Jeremy W. Roy ,&nbsp;Anirban Ghosh ,&nbsp;Stephen M. Lewis ,&nbsp;Rodney J. Ouellette","doi":"10.1016/j.vesic.2023.100033","DOIUrl":"https://doi.org/10.1016/j.vesic.2023.100033","url":null,"abstract":"<div><p>Extracellular vesicles (EVs) are gaining interest as efficient, biocompatible vehicles for cellular delivery of therapeutic cargo. Precipitation-based methods for the isolation of EVs remain popular due to ease of use and lack of requirements for specialized equipment. We describe here a novel charge-based EV isolation method that is simple, scalable, and uses inexpensive polyethylenimine (PEI) polymers. GFP-expressing EVs were isolated from the conditioned cell culture (CCM) media of HEK293-GFP cells using either branched 10 kDa PEI (B-PEI) or linear 25 kDa PEI (L-PEI). Isolated EVs were characterized by Western blotting, nanoparticle tracking analysis, transmission electron microscopy (TEM), and flow cytometry. Western blotting for common EV markers, including CD63, CD9, flotillin-1, and heat shock protein 70 were positive, while GRP94, a marker for cellular contamination, was negative. Isolated EVs had a mean diameter of 146 nm for B-PEI and 175 nm for L-PEI, while TEM revealed a spherical cup-shaped appearance typical of EVs. In addition, we determined that PEI-based EV isolation methods were scalable up to volumes of at least 50 mL. EVs isolated from CCM collected from SUM159 cells that express CD63 fused to a dual EGFP-Renilla-split tag were tested for their ability to reconstitute functional luciferase by delivering the CD63-EGFP-Renilla-split tag to SUM159 recipient cells loaded with a cytopermeable Renilla luciferase substrate. Although EVs isolated using L-PEI behaved similarly to EVs isolated using ultracentrifugation, we observed that EVs isolated using B-PEI produced a more rapid uptake and delivery of active luciferase. In this study we demonstrate that both branched and linear PEI polymers can precipitate EVs from CCM. Furthermore, once eluted from the polymers, the isolated EVs were able to deliver functional protein cargo to recipient cells. Overall, our data support PEI-based isolation of EVs as a simple, rapid method for the recovery of functional EVs.</p></div>","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"3 ","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2773041723000124/pdfft?md5=c7feb4086e774e807af0d19f7fcc7a6f&pid=1-s2.0-S2773041723000124-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139504234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}